Briefing
ZEST: niraparib versus placebo for ctDNA-positive breast cancer after definitive therapy
Phase 3 trial of niraparib versus placebo in patients with triple-negative or BRCA-mutated HER2-negative breast cancer who have ctDNA detected without radiographic recurrence. ClinicalTrials.gov lists the study as active, not recruiting, with 40 patients enrolled.
- Design: Phase 3 · Active, not recruiting